Advances in Clinical Medicine
Vol. 12  No. 10 ( 2022 ), Article ID: 57097 , 6 pages
10.12677/ACM.2022.12101378

常见实验室指标与肺栓塞患者预后的研究进展

郑伟,张怡欣,吕卓航,吴占庆

青海大学附属医院急诊科,青海 西宁

收稿日期:2022年9月21日;录用日期:2022年10月14日;发布日期:2022年10月25日

摘要

肺栓塞(pulmonary embolism, PE)是一种严重的疾病,具有重大的全球性影响。其临床表现缺乏特异性,预后差异极大,因此为首次诊断的科室急诊科带来了巨大的挑战。对PE患者的预后评估是推动其治疗的关键,寻找新的预后因素是更准确地估计短期不良事件的核心问题。本文描述了急诊科常见实验室指标,如血钙、中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值、D-二聚体等对PE患者预后的影响,从而指导PE患者个体化治疗、提高PE患者生存率。

关键词

肺栓塞(PE),预后,综述

Research Progress of Common Laboratory Indicators and Prognosis of Patients with Pulmonary Embolism

Wei Zheng, Yixin Zhang, Zhuohang Lyu, Zhanqing Wu

Emergency Department, The Affiliated Hospital of Qinghai University, Xining Qinghai

Received: Sep. 21st, 2022; accepted: Oct. 14th, 2022; published: Oct. 25th, 2022

ABSTRACT

Pulmonary embolism (PE) is a serious disease with significant global impact. Its clinical presentation lacks specificity and prognosis is highly variable, thus posing a huge challenge to the emergency department for first-time diagnosis. Prognostic assessment of PE patients is the key to promoting their treatment, and finding new prognostic factors is the core issue for more accurate estimation of short-term adverse events. This article describes the impact of common laboratory indicators in the emergency department on the prognosis of PE patients, such as serum calcium, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, D-dimer and so on, to guide individualized treatment of PE patients, improve survival rate of PE patients.

Keywords:Pulmonary Embolism (PE), Prognosis, Review

Copyright © 2022 by author(s) and Hans Publishers Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

1. 引言

胸痛是患者就诊于急诊科的常见的原因之一,2009年在北京进行的一项急诊胸痛注册研究中,胸痛占全部急诊患者的4%,其中急性冠脉综合征(acute coronary syndrome, ACS)患者占27.4%、肺栓塞(pulmonary embolism, PE)占0.2%、主动脉夹层占0.1% [1]。就肺栓塞而言仍然是临床医生关注的一个关键问题,它在急诊科的诊断对临床医生来说更具有挑战性,因为这种潜在的致命性疾病包括高度多变的临床表现。目前PE的典型三联症为胸痛、咯血、呼吸困难,一项三级医院的回顾性研究表明胸痛是PE一种有利的预后指标 [2],且来自德国胸痛单位登记的结果表明伴有胸痛的PE患者就诊于医院的时间明显早于仅有呼吸困难的患者 [3]。

流行病学方面,PE是一个世界性的问题,在西方国家心血管疾病中,其致死率位列第三。一项多中心回顾性研究表明到急诊科就诊的胸痛患者中有30%的人做过肺栓塞检查,而肺栓塞患病率仅为2.6% [4],而基于我国一项调查表明急诊医师对肺栓塞不能及时诊断 [5],且在德国心脏学会认证的专门的胸痛单元中,PE患者存在诊断不足和持续潜在的治疗不足的风险,被认为是预期关注ACS患者的结果 [3]。Masahiro Ota相关研究表明早期识别并治疗PE患者其生存率将大幅度提高 [6],而对于明确诊断为肺栓塞的患者来说,其中有15%在患病后1个月内死亡,30%幸存的患者在未来的10年内复发 [7]。目前主要根据血流动力学、肺栓塞严重程度指数、右心室功能障碍的超声心动图证据、计算机断层扫描血管造影和右室缺血的生物标志物证据进行患者预后的评估,由于就诊于急诊科的PE患者临床表现多样,且无特异性,预后差异较大,因此有必要加强急诊医生对PE的认知以及从简单、快速的实验室指标中找到对PE预后有意义的参考指标。

2. 常见实验室指标对肺栓塞预后的评估

2.1. 血钙

钙离子作为凝血因子IV是凝血级联反应的重要辅助因子,因此可能参与严重血栓栓塞和出血事件的病理生理过程。PE患者血栓形成过程中存在血小板活化,钙离子作为血小板活化的二级信使在凝血通路中扮演着重要角色,细胞外的钙离子在凝血过程中通过内流进入细胞内发挥促凝作用,因此血栓形成需要血小板和钙离子参与,也就伴随着二者的消耗 [8]。Usta等人报告1例56岁女性全髋关节置换术后发生PE可能由低钙血症引发,作者考虑低钙血症继发的下肢痉挛可能是PE的触发因素 [9],Xin Wang的一项病例对照研究共纳入496名患者,显示低钙与PE患者30天死亡率(OR: 2.858, 95% CI: 1.430~5.711, P = 0.003)显著相关,低钙血症患者的死亡率高 [10],Mukunthan Murthi的一项回顾性研究表明低钙血症的PE患者住院死亡率高出仅有PE患者的4倍(OR: 4.03, 95% CI: 2.78~5.84, P < 0.001) [11];然而国内有一项研究表明低血钙能否作为PE患者溶栓治疗短期死亡预测因子仍需进一步研究论证 [12],然而此研究样本量少,并未将影响血钙的因素排除在外,其结论有待进一步明确。迄今为止,低钙血症对PE患者预后的影响报道甚少、结果结论尚不明确,并没有相应的文献综述或荟萃分析阐明其中的联系且存在许多不足,仍然需要大量临床样本资料来明确其在PE患者中的诊断意义。

2.2. 血细胞参数

中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio, NLR)、血小板/淋巴细胞比值(platelet to lymphocyte ratio, PLR)是血常规中的新生标志物,这些标志物很容易从实验室检查结果中获得,并提供有关全身炎症状态的重要信息。炎症因子和凝血因子之间复杂的相互作用在血管疾病的病理生理学中起作用并可能导致血栓栓塞并发症 [13],且PE患者肺组织中有再灌注损伤、氧化应激以及氧自由基的形成,故内皮损伤和炎症在PE发生过程中至关重要 [14]。此前已有众多研究表明NLR、PLR是PE患者短期死亡率的预测指标。临床研究方面Trung Phan表明NLR [8.10 (4.28~13.7) vs 3.91 (2.46~6.71), P < 0.01]和PLR [263 (147~407) vs 148 (95.5~214), P < 0.01)升高与全因死亡率相关 [15],Elif Hande发现PLR是肺栓塞患者长期全因死亡率的显著预测因子(OR: 1.746, 95% CI: 1.211~2.865, P = 0.001) [16]。荟萃分析方面Qian Wang表明NLR、PLR值升高与PE患者总病死率相关(OR值分别为10.13、6.32,P < 0.001) [17],Silvia Galliazzo也表明高NLR与PE短期死亡率相关(敏感度为77%、特异度为74%) [18]。综上,来自常规实验室检查的NLR和PLR能够作为新的生物标志物,成为PE风险预测模型的有用组成部分,但在临床医疗过程中这两个指标常常受到其他因素干扰,在实用性方面这两个指标只有参考价值。

2.3. D-二聚体

血浆D-二聚体是血液中纤维蛋白的降解产物,是反应体内高凝状态和继发纤溶亢进的敏感指标,因此D-二聚体浓度对于血栓疾病的诊断、疗效评估以及预后都有重要的意义。D-二聚体阴性预测价值极高,当D-二聚体 < 1500 ng/mL阴性预测价值是99% [19],能作为PE的排除诊断,而年龄能引起D-二聚体变化,所以为了排除各年龄段诊断为低度、中度的PE患者,通常采用年龄效正的D-二聚体。国外有研究表明D-二聚体应被视为PE患者的潜在预后标志物 [20],与D-二聚体500~2499 ng/mL相比,D-二聚体 > 5000 ng/mL患者总死亡率增加了2.9倍(OR: 2.94, 95% CI: 1.42~6.25, P = 0.032) [21],且在老年PE患者中其预测价值也有效 [22]。因其他疾病如肿瘤、感染、手术等也可引起D-二聚体升高,其水平特异度较低,国外也出现过相反的研究,其中一篇文章回顾性收集了东京CCU网络机构收治的441例急性肺栓塞患者,结果表示30天内死亡的患者D-二聚体没有观察到差异 [23],另一篇研究在98名PE患者中位随访时间55个月期间,11名患者死亡(死亡率为11.2%),两组D-二聚体的死亡率无显著差异(P = 0.798) [24],显著升高的D-二聚体水平并不意味着PE的高死亡率或住院期间的全因死亡率 [25],这3篇大样本病例对照研究的文章均表明D-二聚体水平不是PE预后的良好预测因素。总的来说,D-二聚体对于PE的预后结论不一,缺乏相应的总结,其阴性预测价值有助于排出疾病,阳性预测价值并未表明到达某一特定值PE死亡率就成直线上升,仍需要更加多的研究来验证。

2.4. B型脑钠肽或N端脑钠肽前体、心肌肌钙蛋白

在肺栓塞患者中由于静脉血栓栓子的作用使肺动脉压升高,作为对右心室后负荷突然增加的反应,右心室扩张并变得运动迟缓,最终出现急性故障。B型脑钠肽(brain-type natriuretic peptide, BNP)或N端脑钠肽前体(N-terminal pro brain natriuretic peptide, NT-ProBNP)由心室肌细胞合成和分泌,心室负荷和室壁张力的改变可刺激分泌增加,是提示心力衰竭的指标,心肌肌钙蛋白(cardiac troponin, cTn)是心肌损伤的敏感和特异标记物,这两者在PE分层方面都具有重大的意义。在D-二聚体、NT-ProBNP和cTn预测PE复发和全因死亡的研究中,与具有一个异常标志物的患者相比,具有两个或三个异常标志物的患者的总不良事件风险显着更高 [26],且许多研究评估了PE患者BNP或NT-proBNP、cTn水平升高与短期临床结果的相关性。

NT-proBNP是PE患者不良临床结局的独立预测因子(OR: 14.6, 95% CI: 1.5~139.0, P = 0.033) [27]。对于血流动力学稳定、血浆NT-proBNP水平较低(<500 pg/mL)的PE患者出院治疗是安全的 [28]。cTn阳性者死亡率显著高于阴性者 [23],且cTn升高与PE患者长期预后呈浓度依赖性关系 [29]。荟萃分析方面Anurag Bajaj的两篇研究表明BNP或NT-proBNP与短期死亡和严重不良事件的风险增加相关 [30],cTn水平升高与急性非大面积PE患者短期死亡率、严重不良事件的增加显著相关 [31]。Stefano Barco的荟萃分析也表明低危PE患者cTn与30天死亡率有关 [32]、肌钙蛋白水平升高可确定急性肺栓塞患者的短期死亡和不良事件的高风险 [33]。上诉研究结果呈现出高度的一致性,并且相关荟萃分析已得出结论都表明这3个指标在临床中的应用价值。

2.5. 心型脂肪酸结合蛋白

在ACS和心肌梗死患者中,心型脂肪酸结合蛋白(heart type fatty acid binding protein, H-FABP)水平升高与死亡风险和重大心脏事件的增加相关,在发生心肌损伤的其他情况下(如急性充血性心力衰竭和急性PE等)具有作为预后标志物的潜在作用 [34]。对于急性PE患者,H-FABP可能是由于右心室后负荷高度升高所致的右室壁压力升高的结果。血压正常的急性PE患者或中度风险PE患者,H-FABP可显著的预测其死亡率 [35],此外急性PE发病后24小时内H-FABP阳性率高于cTnI (52/69, 75.4% vs. 28/69, 40.6%, P = 0.003),H-FABP与急性PE患者住院期间的主要不良事件及发病6个月后的主要预后显著相关 [36]。Anna Kaczynska研究表明H-FABP是唯一的30天死亡率预测因子(HR: 1.02, 95% CI, 1.01~1.03, P < 0.01) [37]。荟萃分析也表明高H-FABP水平与不良临床结局发生的高风险相关 [30] [38] [39]。

3. 总结

在急诊科就诊的患者中PE占少许部分,由于其临床表现及体征缺乏特异性,其漏诊率、误诊率较大、相应预后较差,故对于急诊医生来讲,从简单、快速的临床实验室指标中找到与PE预后相关的指标,对于指导PE患者的个体化治疗、提高PE患者生存率格外重要。

低钙血钙对于PE患者预后的预测目前尚无定论,从国外检索的文献来看有2篇文章进行过相应病例对照研究,且样本量大,都表明血钙对于PE的预后有预测意义,而国内的1篇文章,小样本数据,其研究的重点并不在于血钙,并且相应的排除标准不全面,其结论不可靠,由上可看出血钙与PE患者预后的临床研究少,检索相应数据库综述、荟萃分析并没有,其结论仍需进一步考证。

NLR与PLR值在排除其他影响因素后,相应地能为急诊医生更快判断PE患者预后不良、能为急诊患者寻求更加快捷的治疗;D-二聚体水平的阴性预测价值对于肺栓塞诊断格外重要,而在PE预后的研究中,表现出不同的结果,缺乏相应的总结(荟萃分析);BNP或NT-proBNP、cTn、H-FABP对于PE患者预后格外重要,目前已用于PE患者的诊治指南中。

总的来说,在评估PE患者的预后时,单看上诉有意义的指标可能不足,需联合看待检验结果来评估病情,并且有待于更大规模的研究进一步明确。

文章引用

郑 伟,张怡欣,吕卓航,吴占庆. 常见实验室指标与肺栓塞患者预后的研究进展
Research Progress of Common Laboratory Indicators and Prognosis of Patients with Pulmonary Embolism[J]. 临床医学进展, 2022, 12(10): 9528-9533. https://doi.org/10.12677/ACM.2022.12101378

参考文献

  1. 1. 胡大一, 丁荣晶. “胸痛中心”建设中国专家共识[J]. 中华危重症医学杂志(电子版), 2011, 4(6): 381-393.

  2. 2. Wong, C.C., Ng, A.C., Lau, J.K., et al. (2016) The Prognostic Impact of Chest Pain in 1306 Patients Presenting with Confirmed Acute Pulmonary Embolism. International Journal of Cardiology, 221, 794-799. https://doi.org/10.1016/j.ijcard.2016.07.129

  3. 3. Settelmeier, S., Hochadel, M., Giannitsis, E., et al. (2021) Man-agement of Pulmonary Embolism: Results from the German Chest Pain Unit Registry. Cardiology, 146, 304-310. https://doi.org/10.1159/000513695

  4. 4. Lefevre-Scelles, A., Jeanmaire, P., Freund, Y., et al. (2020) Investigation of Pulmonary Embolism in Patients with Chest Pain in the Emergency Department: A Retrospective Multicenter Study. European Journal of Emergency Medicine, 27, 357-361. https://doi.org/10.1097/MEJ.0000000000000680

  5. 5. 北京急诊医学学会血栓与止血分会. 中国急诊医师对静脉血栓栓塞症诊治的认知现状及分析[J]. 中华急诊医学杂志, 2020, 29(8): 1082-1086.

  6. 6. Ota, M., Nakamura, M., Yamada, N., et al. (2002) Prognostic Significance of Early Diagnosis in Acute Pulmonary Thromboembolism with Circulatory Failure. Heart Vessels, 17, 7-11. https://doi.org/10.1007/s003800200036

  7. 7. Søgaard, K.K., Schmidt, M., Pedersen, L., et al. (2014) 30-Year Mortality after Venous Thromboembolism: A Population-Based Cohort Study. Circulation, 130, 829-836. https://doi.org/10.1161/CIRCULATIONAHA.114.009107

  8. 8. Davlouros, P., Xanthopoulou, I., Mparampoutis, N., et al. (2016) Role of Calcium in Platelet Activation: Novel Insights and Pharmacological Implications. Medicinal Chemistry, 12, 131-138. https://doi.org/10.2174/157340641202160208195923

  9. 9. Usta, B., Gozdemir, M., Turgut, F., et al. (2007) Does Hypocalcemia Trigger Pulmonary Embolism? Medical Hypotheses, 68, 464-465. https://doi.org/10.1016/j.mehy.2006.07.047

  10. 10. Wang, X., Xiang, Y., Zhang, T., et al. (2020) Association be-tween Serum Calcium and Prognosis in Patients with Acute Pulmonary Embolism and the Optimization of Pulmonary Embolism Severity Index. Respiratory Research, 21, Article No. 298. https://doi.org/10.1186/s12931-020-01565-z

  11. 11. Murthi, M., Shaka, H., El-Amir, Z., et al. (2021) Association of Hypocalcemia with In-Hospital Mortality and Complications in Patients with Acute Pulmonary Embolism: Results from the 2017 Nationwide Inpatient Sample. BMC Pulmonary Medicine, 21, Article No. 410. https://doi.org/10.1186/s12890-021-01784-0

  12. 12. 乔优, 袁媛, 范俊平, 等. 急性肺栓塞溶栓治疗的短期预后影响因素: 病例对照研究[J]. 协和医学杂志, 2020, 11(2): 144-150.

  13. 13. Levi, M., van der Poll, T. and Büller, H.R. (2004) Bidirectional Relation between Inflammation and Coagulation. Circulation, 109, 2698-2704. https://doi.org/10.1161/01.CIR.0000131660.51520.9A

  14. 14. Oyaizu, T., Fung, S.Y., Shiozaki, A., et al. (2012) Src Tyrosine Kinase Inhibition Prevents Pulmonary Ischemia-Re- perfusion-Induced Acute Lung Injury. Intensive Care Medicine, 38, 894-905. https://doi.org/10.1007/s00134-012-2498-z

  15. 15. Phan, T., Brailovsky, Y., Fareed, J., et al. (2020) Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict All-Cause Mortality in Acute Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis, 26, 1-7. https://doi.org/10.1177/1076029619900549

  16. 16. Ozcan Cetin, E.H., Cetin, M.S., Canpolat, U., et al. (2017) Plate-let-to-Lymphocyte Ratio as a Novel Marker of In-Hospital and Long-Term Adverse Outcomes among Patients with Acute Pulmonary Embolism: A Single Center Large-Scale Study. Thrombosis Research, 150, 33-40. https://doi.org/10.1016/j.thromres.2016.12.006

  17. 17. Wang, Q., Ma, J., Jiang, Z., et al. (2018) Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lym- phocyte Ratio in Acute Pulmonary Embolism: A Systematic Re-view and Meta-Analysis. International Angiology, 37, 4-11. https://doi.org/10.23736/S0392-9590.17.03848-2

  18. 18. Galliazzo, S., Nigro, O., Bertù, L., et al. (2018) Prognostic Role of Neutrophils to Lymphocytes Ratio in Patients with Acute Pulmonary Embolism: A Systematic Review and Me-ta-Analysis of the Literature. Internal and Emergency Medicine, 13, 603-608. https://doi.org/10.1007/s11739-018-1805-2

  19. 19. Aujesky, D., Roy, P.M., Guy, M., et al. (2006) Prognostic Value of D-Dimer in Patients with Pulmonary Embolism. Thrombosis and Haemostasis, 96, 478-482. https://doi.org/10.1160/TH06-07-0416

  20. 20. Becattini, C., Lignani, A., Masotti, L., et al. (2012) D-Dimer for Risk Stratification in Patients with Acute Pulmonary Embolism. Journal of Thrombosis and Haemostasis, 33, 48-57. https://doi.org/10.1007/s11239-011-0648-8

  21. 21. Grau, E., Tenías, J.M., Soto, M.J., et al. (2007) D-Dimer Levels Correlate with Mortality in Patients with Acute Pulmonary Embolism: Findings from the RIETE Registry. Critical Care Medicine, 35, 1937-1941. https://doi.org/10.1097/01.CCM.0000277044.25556.93

  22. 22. Polo Friz, H., Buzzini, C., Orenti, A., et al. (2016) Prognostic Value of D-Dimer in Elderly Patients with Pulmonary Embolism. Journal of Thrombosis and Haemostasis, 42, 386-392. https://doi.org/10.1007/s11239-016-1394-8

  23. 23. Tanabe, Y., Obayashi, T., Yamamoto, T., et al. (2015) Predictive Value of Biomarkers for the Prognosis of Acute Pulmonary Embolism in Japanese Patients: Results of the Tokyo CCU Network Registry. Journal of Cardiology, 66, 460-465. https://doi.org/10.1016/j.jjcc.2015.03.002

  24. 24. Geissenberger, F., Schwarz, F., Probst, M., et al. (2019) D-Dimer Predicts Disease Severity but Not Long-Term Prognosis in Acute Pulmonary Embolism. Clinical and Applied Throm-bosis/Hemostasis, 25, 1-7. https://doi.org/10.1177/1076029619863495

  25. 25. Stein, P.D., Janjua, M., Matta, F., et al. (2011) Prognostic Value of D-Dimer in Stable Patients with Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis, 17, E183-E185. https://doi.org/10.1177/1076029610395129

  26. 26. Liu, X., Zheng, L., Han, J., et al. (2021) Joint Analysis of D-Dimer, N-Terminal pro b-Type Natriuretic Peptide, and Cardiac Troponin I on Predicting Acute Pulmonary Embolism Relapse and Mortality. Scientific Reports, 11, Article No. 14909. https://doi.org/10.1038/s41598-021-94346-7

  27. 27. Kucher, N., Printzen, G., Doernhoefer, T., et al. (2003) Low Pro-Brain Natriuretic Peptide Levels Predict Benign Clinical Outcome in Acute Pulmonary Embolism. Circulation, 107, 1576-1578. https://doi.org/10.1161/01.CIR.0000064898.51892.09

  28. 28. Agterof, M.J., Schutgens, R.E., Snijder, R.J., et al. (2010) Out of Hospital Treatment of Acute Pulmonary Embolism in Patients with a Low NT-proBNP Level. Journal of Thrombosis and Haemostasis, 8, 1235-1241. https://doi.org/10.1111/j.1538-7836.2010.03831.x

  29. 29. Ng, A.C., Yong, A.S., Chow, V., et al. (2013) Cardiac Troponin-T and the Prediction of Acute and Long-Term Mortality after Acute Pulmonary Embolism. International Jour-nal of Cardiology, 165, 126-133. https://doi.org/10.1016/j.ijcard.2011.07.107

  30. 30. Bajaj, A., Rathor, P., Sehgal, V., et al. (2015) Prognostic Value of Biomarkers in Acute Non-Massive Pulmonary Embolism: A Systematic Review and Meta-Analysis. Lung, 193, 639-651. https://doi.org/10.1007/s00408-015-9752-4

  31. 31. Bajaj, A., Saleeb, M., Rathor, P., et al. (2015) Prognostic Value of Troponins in Acute Nonmassive Pulmonary Embolism: A Meta-Analysis. Heart Lung, 44, 327-334. https://doi.org/10.1016/j.hrtlng.2015.03.007

  32. 32. Barco, S., Mahmoudpour, S.H., Planquette, B., et al. (2019) Prognostic Value of Right Ventricular Dysfunction or Elevated Cardiac Biomarkers in Patients with Low-Risk Pulmo-nary Embolism: A Systematic Review and Meta-Analysis. European Heart Journal, 40, 902-910. https://doi.org/10.1093/eurheartj/ehy873

  33. 33. Becattini, C., Vedovati, M.C. and Agnelli, G. (2007) Prognostic Val-ue of Troponins in Acute Pulmonary Embolism: A Meta-Analysis. Circulation, 116, 427-433. https://doi.org/10.1161/CIRCULATIONAHA.106.680421

  34. 34. Goel, H., Melot, J., Krinock, M.D., et al. (2020) Heart-Type Fatty Acid-Binding Protein: An Overlooked Cardiac Biomarker. Annals of Medicine, 52, 444-461. https://doi.org/10.1080/07853890.2020.1800075

  35. 35. Langer, M., Forkmann, M., Richter, U., et al. (2016) Heart-Type Fatty Acid-Binding Protein and Myocardial Creatine Kinase Enable Rapid Risk Stratification in Normoten-sive Patients with Pulmonary Embolism. Journal of Critical Care, 35, 174-179. https://doi.org/10.1016/j.jcrc.2016.05.014

  36. 36. Qian, H.Y., Huang, J., Yang, Y.J., et al. (2016) Heart-Type Fatty Acid Binding Protein in the Assessment of Acute Pulmonary Embolism. The American Journal of the Medical Sciences, 352, 557-562. https://doi.org/10.1016/j.amjms.2016.08.018

  37. 37. Kaczyñska, A., Pelsers, M.M., Bochowicz, A., et al. (2006) Plasma Heart-Type Fatty Acid Binding Protein Is Superior to Troponin and Myoglobin for Rapid Risk Stratification in Acute Pulmonary Embolism. Clinica Chimica Acta, 371, 117-123. https://doi.org/10.1016/j.cca.2006.02.032

  38. 38. Liu, M., Yuan, X., Qiu, X., et al. (2015) Prognostic Role of Heart-Type Fatty Acid Binding Protein in Pulmonary Embolism: A Meta-Analysis. Thrombosis Research, 135, 20-25. https://doi.org/10.1016/j.thromres.2014.10.007

  39. 39. Bajaj, A., Rathor, P., Sehgal, V., et al. (2015) Risk Stratifica-tion in Acute Pulmonary Embolism with Heart-Type Fatty Acid-Binding Protein: A Meta-Analysis. Journal of Critical Care, 30, 1151.e1151-1157. https://doi.org/10.1016/j.jcrc.2015.05.026

期刊菜单